Virus-specific T cell therapy to treat refractory viral infections in solid organ transplant recipients

Solid organ transplant recipients require ongoing immunosuppression to prevent acute rejection, which puts them at risk for opportunistic infections. Viral infections are particularly challenging to prevent and treat as many establish latency and thus cannot be eliminated, while targets for small molecule antiviral medications are limited. Resistance to antivirals and unacceptable toxicity also complicate treatment. Virus specific T cell therapies aim to restore host specific immunity to opportunistic viruses that is lacking due to ongoing immunosuppressive therapy. This minireview will provide a state-of-the-art update of the current virus specific T cell pipeline and translational research that is likely to lead to further treatment options for viral infections in solid organ transplant recipients.